Cargando…

The clinical role of the TME in solid cancer

The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraldo, Nicolas A., Sanchez-Salas, Rafael, Peske, J. David, Vano, Yann, Becht, Etienne, Petitprez, Florent, Validire, Pierre, Ingels, Alexandre, Cathelineau, Xavier, Fridman, Wolf Herman, Sautès-Fridman, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325164/
https://www.ncbi.nlm.nih.gov/pubmed/30413828
http://dx.doi.org/10.1038/s41416-018-0327-z
_version_ 1783386090018701312
author Giraldo, Nicolas A.
Sanchez-Salas, Rafael
Peske, J. David
Vano, Yann
Becht, Etienne
Petitprez, Florent
Validire, Pierre
Ingels, Alexandre
Cathelineau, Xavier
Fridman, Wolf Herman
Sautès-Fridman, Catherine
author_facet Giraldo, Nicolas A.
Sanchez-Salas, Rafael
Peske, J. David
Vano, Yann
Becht, Etienne
Petitprez, Florent
Validire, Pierre
Ingels, Alexandre
Cathelineau, Xavier
Fridman, Wolf Herman
Sautès-Fridman, Catherine
author_sort Giraldo, Nicolas A.
collection PubMed
description The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)—in particular, the degree of tumour infiltration by cytotoxic T cells—can predict a patient’s clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective.
format Online
Article
Text
id pubmed-6325164
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63251642019-11-09 The clinical role of the TME in solid cancer Giraldo, Nicolas A. Sanchez-Salas, Rafael Peske, J. David Vano, Yann Becht, Etienne Petitprez, Florent Validire, Pierre Ingels, Alexandre Cathelineau, Xavier Fridman, Wolf Herman Sautès-Fridman, Catherine Br J Cancer Review Article The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)—in particular, the degree of tumour infiltration by cytotoxic T cells—can predict a patient’s clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective. Nature Publishing Group UK 2018-11-09 2019-01-08 /pmc/articles/PMC6325164/ /pubmed/30413828 http://dx.doi.org/10.1038/s41416-018-0327-z Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Review Article
Giraldo, Nicolas A.
Sanchez-Salas, Rafael
Peske, J. David
Vano, Yann
Becht, Etienne
Petitprez, Florent
Validire, Pierre
Ingels, Alexandre
Cathelineau, Xavier
Fridman, Wolf Herman
Sautès-Fridman, Catherine
The clinical role of the TME in solid cancer
title The clinical role of the TME in solid cancer
title_full The clinical role of the TME in solid cancer
title_fullStr The clinical role of the TME in solid cancer
title_full_unstemmed The clinical role of the TME in solid cancer
title_short The clinical role of the TME in solid cancer
title_sort clinical role of the tme in solid cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325164/
https://www.ncbi.nlm.nih.gov/pubmed/30413828
http://dx.doi.org/10.1038/s41416-018-0327-z
work_keys_str_mv AT giraldonicolasa theclinicalroleofthetmeinsolidcancer
AT sanchezsalasrafael theclinicalroleofthetmeinsolidcancer
AT peskejdavid theclinicalroleofthetmeinsolidcancer
AT vanoyann theclinicalroleofthetmeinsolidcancer
AT bechtetienne theclinicalroleofthetmeinsolidcancer
AT petitprezflorent theclinicalroleofthetmeinsolidcancer
AT validirepierre theclinicalroleofthetmeinsolidcancer
AT ingelsalexandre theclinicalroleofthetmeinsolidcancer
AT cathelineauxavier theclinicalroleofthetmeinsolidcancer
AT fridmanwolfherman theclinicalroleofthetmeinsolidcancer
AT sautesfridmancatherine theclinicalroleofthetmeinsolidcancer
AT giraldonicolasa clinicalroleofthetmeinsolidcancer
AT sanchezsalasrafael clinicalroleofthetmeinsolidcancer
AT peskejdavid clinicalroleofthetmeinsolidcancer
AT vanoyann clinicalroleofthetmeinsolidcancer
AT bechtetienne clinicalroleofthetmeinsolidcancer
AT petitprezflorent clinicalroleofthetmeinsolidcancer
AT validirepierre clinicalroleofthetmeinsolidcancer
AT ingelsalexandre clinicalroleofthetmeinsolidcancer
AT cathelineauxavier clinicalroleofthetmeinsolidcancer
AT fridmanwolfherman clinicalroleofthetmeinsolidcancer
AT sautesfridmancatherine clinicalroleofthetmeinsolidcancer